PriceTargets.com logo

OptiNose - OPTN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 140.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.25 As of 11/30/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for OPTN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OptiNose Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPTN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPTN

Analyst Price Target is $3.00
▲ +140.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for OptiNose in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 140.00% upside from the last price of $1.25.

This chart shows the closing price for OPTN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in OptiNose. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/21/2023Lake Street CapitalInitiated CoverageBuy$3.00Low
8/11/2023Piper SandlerLower TargetOverweight ➝ Overweight$4.00 ➝ $3.00Low
11/16/2022Piper SandlerLower Target$4.00Low
11/14/2022BMO Capital MarketsLower TargetOutperform$6.00 ➝ $5.00Low
10/21/2022Jefferies Financial GroupInitiated CoverageBuy$5.00Low
11/30/2021Cantor FitzgeraldReiterated RatingOverweightLow
11/17/2021BMO Capital MarketsLower TargetOutperform$16.00 ➝ $9.00Low
5/6/2021Royal Bank of CanadaLower Target$17.00 ➝ $10.00Medium
5/6/2021Cantor FitzgeraldLower TargetOverweight$18.00 ➝ $12.00High
7/16/2020Piper SandlerReiterated RatingOverweight ➝ Market Perform$19.00Medium
7/16/2020Royal Bank of CanadaReiterated RatingOutperform$17.00Medium
3/25/2020Royal Bank of CanadaReiterated RatingBuy$17.00Low
3/5/2020Cantor FitzgeraldLower TargetOverweight$27.00 ➝ $21.00High
2/7/2020Piper SandlerReiterated RatingBuy$24.00Low
12/18/2019CowenInitiated CoverageOutperform$25.00Low
8/13/2019BMO Capital MarketsLower TargetOutperform$26.00 ➝ $24.00High
8/12/2019Royal Bank of CanadaSet TargetBuy$20.00Low
5/9/2019Cantor FitzgeraldReiterated RatingBuy$27.00High
4/23/2019Piper Sandler CompaniesSet TargetBuy$29.00Low
3/7/2019Royal Bank of CanadaLower TargetOutperform$25.00High
2/4/2019Cantor FitzgeraldReiterated RatingBuy$27.00High
(Data available from 11/30/2018 forward)

News Sentiment Rating

0.85 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/2/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023

Current Sentiment

  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

OptiNose logo
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Read More

Today's Range

Now: $1.25
Low: $1.23
High: $1.27

50 Day Range

MA: $1.21
Low: $1.03
High: $1.26

52 Week Range

Now: $1.25
Low: $0.90
High: $2.07

Volume

431,447 shs

Average Volume

345,422 shs

Market Capitalization

$140.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OptiNose?

The following sell-side analysts have issued reports on OptiNose in the last twelve months: Lake Street Capital, and Piper Sandler.
View the latest analyst ratings for OPTN.

What is the current price target for OptiNose?

2 Wall Street analysts have set twelve-month price targets for OptiNose in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 140.0%. Lake Street Capital has the highest price target set, predicting OPTN will reach $3.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $3.00 for OptiNose in the next year.
View the latest price targets for OPTN.

What is the current consensus analyst rating for OptiNose?

OptiNose currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPTN will outperform the market and that investors should add to their positions of OptiNose.
View the latest ratings for OPTN.

What other companies compete with OptiNose?

Other companies that are similar to OptiNose include Esperion Therapeutics, Annexon, Ventyx Biosciences, Praxis Precision Medicines and Aquestive Therapeutics. Learn More about companies similar to OptiNose.

How do I contact OptiNose's investor relations team?

OptiNose's physical mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company's listed phone number is (267) 364-3500 and its investor relations email address is [email protected]. The official website for OptiNose is www.optinose.com. Learn More about contacing OptiNose investor relations.